Human ELOVL7 activation kit by CRISPRa

CAT#: GA112777

ELOVL7 CRISPRa kit - CRISPR gene activation of human ELOVL fatty acid elongase 7



  See Other Versions

CNY 12255.00


货期*
4周

规格
    • 1 kit

Product images

推荐一起购买 (3)
Rabbit Polyclonal ELOVL7 Antibody
    • 100 ug

CNY 5808.00


ELOVL7 (Myc-DDK-tagged)-Human ELOVL fatty acid elongase 7 (ELOVL7), transcript variant 1
    • 10 ug

CNY 3600.00
CNY 3990.00


Rabbit Polyclonal Anti-ELOVL7 Antibody
    • 100 ul

CNY 5250.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol ELOVL7
Locus ID 79993
Kit Components

GA112777G1, ELOVL7 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA112777G2, ELOVL7 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA112777G3, ELOVL7 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Reference Data
RefSeq NM_001104558, NM_001297617, NM_001297618, NM_024930
Synonyms FLJ23563
Summary Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme with higher activity toward C18 acyl-CoAs, especially C18:3(n-3) acyl-CoAs and C18:3(n-6)-CoAs. Also active toward C20:4-, C18:0-, C18:1-, C18:2- and C16:0-CoAs, and weakly toward C20:0-CoA. Little or no activity toward C22:0-, C24:0-, or C26:0-CoAs. May participate in the production of saturated and polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators.[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...